Off-the-shelf T-cell specialist hits buffers with mid-stage flop

10 November 2023
2020_biotech_lab_vial_research_big

A Phase II failure for Californian cell therapy company Atara Biotherapeutics (Nasdaq: ATRA) has prompted a share sell-off, with the company’s stock falling 80% in value on Thursday.

The immunotherapy specialist is using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for people with cancer and autoimmune diseases.

Primary analysis data show that the Phase II EMBOLD study of ATA188 did not meet its primary endpoint, with fluid and imaging biomarkers also failing to provide evidence of efficacy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology